Connection
Virginia Borges to Neoplasm, Residual
This is a "connection" page, showing publications Virginia Borges has written about Neoplasm, Residual.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.044 |
|
|
|
-
O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1?+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021 Dec; 17(34):4665-4676.
Score: 0.044